LAS 41001Alternative Names: LAS-41001
Latest Information Update: 14 Apr 2010
At a glance
- Originator Laboratorios Almirall
- Developer Almirall S.A.
- Mechanism of Action Retinoic acid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rosacea
Most Recent Events
- 11 May 2009 Preregistration for Rosacea in European Union (PO)